<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ecam</journal-id><journal-id journal-id-type="hwp">ecam</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18955318</article-id><article-id pub-id-type="pmc">2887326</article-id><article-id pub-id-type="doi">10.1093/ecam/nen003</article-id><article-id pub-id-type="publisher-id">nen003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles - Clinical Analyses</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of a Traditional Herbal Medicine, <italic>Hochu-ekki-to</italic> in the Long-term Management of <italic>Kikyo</italic> (Delicate Constitution) Patients with Atopic Dermatitis: A 6-month, Multicenter, Double-blind, Randomized, Placebo-controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kobayashi</surname><given-names>Hiromi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ishii</surname><given-names>Masamitsu</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shintani</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="AFF1"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamatodani</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kusunoki</surname><given-names>Tadashi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Furue</surname><given-names>Masutaka</given-names></name><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref></contrib></contrib-group><aff id="AFF1"><sup>1</sup>Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, <sup>2</sup>Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, <sup>3</sup>Tanaka Clinic, Nagasaki, <sup>4</sup>Research Institute of Oriental Medicine, Kinki University, Osaka-Sayama, <sup>5</sup>Department of Medical Physics and Engineering, Graduate School of Allied Health Sciences, Faculty of Medicine, Osaka University, Osaka and <sup>6</sup>Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, Tokyo, Japan</aff><author-notes><corresp>For reprints and all correspondence: Hiromi Kobayashi, MD, PhD, Department of Dermatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. Tel: <phone>+81-6-6645-3826</phone>; Fax: <fax>+81-6-6645-3828</fax>; E-mail: <email>hiromik@med.osaka-cu.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2008</year></pub-date><volume>7</volume><issue>3</issue><fpage>367</fpage><lpage>373</lpage><history><date date-type="received"><day>9</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>© 2008 The Author(s).</copyright-statement><copyright-year>2008</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><italic><offsets xml_i="4761" xml_f="4774" txt_i="11" txt_f="24">Hochu-ekki-to</offsets></italic><offsets xml_i="4783" xml_f="4879" txt_i="24" txt_f="120"> is a traditional herbal (Kampo) medicine that has been shown to be effective for patients with </offsets><italic><offsets xml_i="4887" xml_f="4892" txt_i="120" txt_f="125">Kikyo</offsets></italic><offsets xml_i="4901" xml_f="5149" txt_i="125" txt_f="373"> (delicate, easily fatigable, or hypersensitive) constitution. Previous case reports have suggested that this herbal drug was effective for a certain subgroup of patients with atopic dermatitis (AD). We aimed to evaluate the efficacy and safety of </offsets><italic><offsets xml_i="5157" xml_f="5170" txt_i="373" txt_f="386">Hochu-ekki-to</offsets></italic><offsets xml_i="5179" xml_f="5211" txt_i="386" txt_f="418"> in the long-term management of </offsets><italic><offsets xml_i="5219" xml_f="5224" txt_i="418" txt_f="423">Kikyo</offsets></italic><offsets xml_i="5233" xml_f="5328" txt_i="423" txt_f="518"> patients with AD. In this multicenter, double blind, randomized, placebo-controlled study, 91 </offsets><italic><offsets xml_i="5336" xml_f="5341" txt_i="518" txt_f="523">Kikyo</offsets></italic><offsets xml_i="5350" xml_f="5383" txt_i="523" txt_f="556"> patients with AD were enrolled. </offsets><italic><offsets xml_i="5391" xml_f="5396" txt_i="556" txt_f="561">Kikyo</offsets></italic><offsets xml_i="5405" xml_f="5627" txt_i="561" txt_f="783"> condition was evaluated by a questionnaire scoring system. All patients continued their ordinary treatments (topical steroids, topical tacrolimus, emollients or oral antihistamines) before and after their protocol entry. </offsets><italic><offsets xml_i="5635" xml_f="5648" txt_i="783" txt_f="796">Hochu-ekki-to</offsets></italic><offsets xml_i="5657" xml_f="6115" txt_i="796" txt_f="1254"> or placebo was orally administered twice daily for 24 weeks. The skin severity scores, total equivalent amount (TEA) of topical agents used for AD treatment, prominent efficacy (cases with skin severity score = 0 at the end of the study) rate and aggravated rate (more than 50% increase of TEA of topical agents from the beginning of the study) were monitored and evaluated. Seventy-seven out of 91 enrolled patients completed the 24-week treatment course (</offsets><italic><offsets xml_i="6123" xml_f="6136" txt_i="1254" txt_f="1267">Hochu-ekki-to</offsets></italic><offsets xml_i="6145" xml_f="6147" txt_i="1267" txt_f="1269">: </offsets><italic><offsets xml_i="6155" xml_f="6156" txt_i="1269" txt_f="1270">n</offsets></italic><offsets xml_i="6165" xml_f="6181" txt_i="1270" txt_f="1286"> = 37, placebo: </offsets><italic><offsets xml_i="6189" xml_f="6190" txt_i="1286" txt_f="1287">n</offsets></italic><offsets xml_i="6199" xml_f="6281" txt_i="1287" txt_f="1369"> = 40). The TEA of topical agents (steroids and/or tacrolimus) was significantly (</offsets><italic><offsets xml_i="6289" xml_f="6290" txt_i="1369" txt_f="1370">P</offsets></italic><offsets xml_i="6299" xml_f="6324" txt_i="1370" txt_f="1392"> &lt; 0.05) lower in the </offsets><italic><offsets xml_i="6332" xml_f="6345" txt_i="1392" txt_f="1405">Hochu-ekki-to</offsets></italic><offsets xml_i="6354" xml_f="6517" txt_i="1405" txt_f="1568"> group than in the placebo group, although the overall skin severity scores were not statistically different. The prominent efficacy rate was 19% (7 of 37) in the </offsets><italic><offsets xml_i="6525" xml_f="6538" txt_i="1568" txt_f="1581">Hochu-ekki-to</offsets></italic><offsets xml_i="6547" xml_f="6593" txt_i="1581" txt_f="1627"> group and 5% (2 of 40) in the placebo group (</offsets><italic><offsets xml_i="6601" xml_f="6602" txt_i="1627" txt_f="1628">P</offsets></italic><offsets xml_i="6611" xml_f="6660" txt_i="1628" txt_f="1677"> = 0.06). The aggravated rate was significantly (</offsets><italic><offsets xml_i="6668" xml_f="6669" txt_i="1677" txt_f="1678">P</offsets></italic><offsets xml_i="6678" xml_f="6703" txt_i="1678" txt_f="1700"> &lt; 0.05) lower in the </offsets><italic><offsets xml_i="6711" xml_f="6724" txt_i="1700" txt_f="1713">Hochu-ekki-to</offsets></italic><offsets xml_i="6733" xml_f="6955" txt_i="1713" txt_f="1935"> group (3%; 1 of 37) than in the placebo group (18%; 7 of 39). Only mild adverse events such as nausea and diarrhea were noted in both groups without statistical difference. This placebo-controlled study demonstrates that </offsets><italic><offsets xml_i="6963" xml_f="6976" txt_i="1935" txt_f="1948">Hochu-ekki-to</offsets></italic><offsets xml_i="6985" xml_f="7054" txt_i="1948" txt_f="2017"> is a useful adjunct to conventional treatments for AD patients with </offsets><italic><offsets xml_i="7062" xml_f="7067" txt_i="2017" txt_f="2022">Kikyo</offsets></italic><offsets xml_i="7076" xml_f="7098" txt_i="2022" txt_f="2044"> constitution. Use of </offsets><italic><offsets xml_i="7106" xml_f="7119" txt_i="2044" txt_f="2057">Hochu-ekki-to</offsets></italic><offsets xml_i="7128" xml_f="7243" txt_i="2057" txt_f="2172"> significantly reduces the dose of topical steroids and/or tacrolimus used for AD treatment without aggravating AD.</offsets></p></abstract><kwd-group><kwd>atopic dermatitis</kwd><kwd><italic>Hochu-ekki-to</italic></kwd><kwd>Kampo medicine</kwd><kwd>randomized controlled trial</kwd><kwd>steroid</kwd><kwd>tacrolimus</kwd><kwd>(traditional) herbal medicine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="7550" xml_f="7562" txt_i="2180" txt_f="2192">Introduction</offsets></title><p><offsets xml_i="7573" xml_f="7674" txt_i="2193" txt_f="2294">Atopic dermatitis (AD) is a common, chronic, relapsing eczematous skin disease with severe pruritus (</offsets><xref ref-type="bibr" rid="B1 B2 B3"><offsets xml_i="7711" xml_f="7714" txt_i="2294" txt_f="2297">1–3</offsets></xref><offsets xml_i="7721" xml_f="7780" txt_i="2297" txt_f="2356">). The incidence of AD appears to be increasing worldwide (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7811" xml_f="7812" txt_i="2356" txt_f="2357">4</offsets></xref><offsets xml_i="7819" xml_f="7820" txt_i="2357" txt_f="2358">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7851" xml_f="7852" txt_i="2358" txt_f="2359">5</offsets></xref><offsets xml_i="7859" xml_f="7955" txt_i="2359" txt_f="2455">), among which the percentage of adolescent- and adult-type AD cases have also been increasing (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7986" xml_f="7987" txt_i="2455" txt_f="2456">6</offsets></xref><offsets xml_i="7994" xml_f="7995" txt_i="2456" txt_f="2457">,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8026" xml_f="8027" txt_i="2457" txt_f="2458">7</offsets></xref><offsets xml_i="8034" xml_f="8259" txt_i="2458" txt_f="2683">). The precise pathogenesis of AD remains obscure and appears complex. Topical steroids, topical tacrolimus, emollients and oral antihistamines are used as the first-line treatments in standard therapeutic guidelines for AD (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8290" xml_f="8291" txt_i="2683" txt_f="2684">2</offsets></xref><offsets xml_i="8298" xml_f="8299" txt_i="2684" txt_f="2685">,</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="8330" xml_f="8331" txt_i="2685" txt_f="2686">3</offsets></xref><offsets xml_i="8338" xml_f="8339" txt_i="2686" txt_f="2687">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8370" xml_f="8371" txt_i="2687" txt_f="2688">8</offsets></xref><offsets xml_i="8378" xml_f="8681" txt_i="2688" txt_f="2991">). However, long-term application of topical steroids could induce local adverse effects such as skin atrophy and telangiectasia in a substantial number of patients. Topical tacrolimus is a potent calcineurin inhibitor that does not exhibit the hormonal adverse effects associated with steroid therapy (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8712" xml_f="8713" txt_i="2991" txt_f="2992">9</offsets></xref><offsets xml_i="8720" xml_f="8721" txt_i="2992" txt_f="2993">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8753" xml_f="8755" txt_i="2993" txt_f="2995">10</offsets></xref><offsets xml_i="8762" xml_f="8880" txt_i="2995" txt_f="3113">). The major adverse effect in using topical tacrolimus is sensation of skin burning or irritation after application (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8912" xml_f="8914" txt_i="3113" txt_f="3115">11</offsets></xref><offsets xml_i="8921" xml_f="9133" txt_i="3115" txt_f="3327">). In addition, the Food and Drug Administration (FDA) has issued a public health advisory to inform healthcare professionals and patients of a potential cancer risk by the use of topical calcineurin inhibitors (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01343.html"><offsets xml_i="9233" xml_f="9289" txt_i="3327" txt_f="3383">http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01343.html</offsets></ext-link><offsets xml_i="9300" xml_f="9897" txt_i="3383" txt_f="3980">). This concern is based on animal studies, case reports with a small number of patients, or knowledge of the drug's action mechanism as immunosuppressant. According to the FDA statement, it may take human studies of 10 years or longer to determine if the use of topical calcineurin inhibitors is actually linked to cancer development in human. These adverse effects and emotional fear of long-term use of topical steroids and/or tacrolimus have caused topical steroid/tacrolimus phobia in substantial number of patients with AD worldwide who would like to avoid these topical agents if possible (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="9929" xml_f="9931" txt_i="3980" txt_f="3982">12</offsets></xref><offsets xml_i="9938" xml_f="10219" txt_i="3982" txt_f="4263">). Moreover, clinical experience has shown that some of AD patients are really refractory to these conventional treatments, and indeed current AD therapeutic guidelines recommend further intensive treatments such as ultraviolet phototherapy or oral cyclosporine for such patients (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10250" xml_f="10251" txt_i="4263" txt_f="4264">8</offsets></xref><offsets xml_i="10258" xml_f="10260" txt_i="4264" txt_f="4266">).</offsets></p><p><offsets xml_i="10267" xml_f="10410" txt_i="4267" txt_f="4410">In Japan, an alternative approach has been pursued to treat these grave and/or refractory AD patients with traditional herbal medicine such as </offsets><italic><offsets xml_i="10418" xml_f="10433" txt_i="4410" txt_f="4425">Saiko-seikan-to</offsets></italic><offsets xml_i="10442" xml_f="10444" txt_i="4425" txt_f="4427">, </offsets><italic><offsets xml_i="10452" xml_f="10461" txt_i="4427" txt_f="4436">Shohu-san</offsets></italic><offsets xml_i="10470" xml_f="10472" txt_i="4436" txt_f="4438">, </offsets><italic><offsets xml_i="10480" xml_f="10494" txt_i="4438" txt_f="4452">Oren-gedoku-to</offsets></italic><offsets xml_i="10503" xml_f="10505" txt_i="4452" txt_f="4454">, </offsets><italic><offsets xml_i="10513" xml_f="10532" txt_i="4454" txt_f="4473">Byakko-ka-ninjin-to</offsets></italic><offsets xml_i="10541" xml_f="10543" txt_i="4473" txt_f="4475">, </offsets><italic><offsets xml_i="10551" xml_f="10565" txt_i="4475" txt_f="4489">Tokaku-joki-to</offsets></italic><offsets xml_i="10574" xml_f="10576" txt_i="4489" txt_f="4491">, </offsets><italic><offsets xml_i="10584" xml_f="10592" txt_i="4491" txt_f="4499">Unkei-to</offsets></italic><offsets xml_i="10601" xml_f="10603" txt_i="4499" txt_f="4501">, </offsets><italic><offsets xml_i="10611" xml_f="10624" txt_i="4501" txt_f="4514">Hochu-ekki-to</offsets></italic><offsets xml_i="10633" xml_f="10645" txt_i="4514" txt_f="4526"> and so on (</offsets><xref ref-type="bibr" rid="B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33"><offsets xml_i="10757" xml_f="10762" txt_i="4526" txt_f="4531">13–33</offsets></xref><offsets xml_i="10769" xml_f="10997" txt_i="4531" txt_f="4759">). These prescriptions comprise several elemental herbs, combined use of which is thought to help increase the treatment effects and to diminish adverse reactions of each individual herb. Among these prescriptions, formula like </offsets><italic><offsets xml_i="11005" xml_f="11019" txt_i="4759" txt_f="4773">Tokaku-joki-to</offsets></italic><offsets xml_i="11028" xml_f="11086" txt_i="4773" txt_f="4831"> are mainly aimed at eliminating disease factors, whereas </offsets><italic><offsets xml_i="11094" xml_f="11107" txt_i="4831" txt_f="4844">Hochu-ekki-to</offsets></italic><offsets xml_i="11116" xml_f="11297" txt_i="4844" txt_f="5025"> is aimed at correcting abnormal homeostasis of the body. Each prescription is selected individually according to the pharmacological features and the constitution of each patient. </offsets><italic><offsets xml_i="11305" xml_f="11318" txt_i="5025" txt_f="5038">Hochu-ekki-to</offsets></italic><offsets xml_i="11327" xml_f="11425" txt_i="5038" txt_f="5136"> is composed of hot water extracts from 10 species of herbal plants and is used for patients with </offsets><italic><offsets xml_i="11433" xml_f="11438" txt_i="5136" txt_f="5141">Kikyo</offsets></italic><offsets xml_i="11447" xml_f="11462" txt_i="5141" txt_f="5156"> constitution. </offsets><italic><offsets xml_i="11470" xml_f="11475" txt_i="5156" txt_f="5161">Kikyo</offsets></italic><offsets xml_i="11484" xml_f="11503" txt_i="5161" txt_f="5180">, or deficiency of </offsets><italic><offsets xml_i="11511" xml_f="11513" txt_i="5180" txt_f="5182">Ki</offsets></italic><offsets xml_i="11522" xml_f="11683" txt_i="5182" txt_f="5343">, is defined as delicate, easily fatigable, or hypersensitive constitution typically associated with poor gastrointestinal functions, anorexia and night sweats (</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="11715" xml_f="11717" txt_i="5343" txt_f="5345">34</offsets></xref><offsets xml_i="11724" xml_f="11783" txt_i="5345" txt_f="5404">). In experiments using animal models, orally administered </offsets><italic><offsets xml_i="11791" xml_f="11804" txt_i="5404" txt_f="5417">Hochu-ekki-to</offsets></italic><offsets xml_i="11813" xml_f="12116" txt_i="5417" txt_f="5720"> exhibits various immunopharmacological effects, especially anti-allergic properties. They include suppression of serum IgE level and eosinophil infiltration and improvement of dermatitis through controlling Th1/Th2 balance possibly by inducing interferon γ production from intraepithelial lymphocytes (</offsets><xref ref-type="bibr" rid="B35 B36 B37 B38 B39 B40 B41 B42"><offsets xml_i="12176" xml_f="12181" txt_i="5720" txt_f="5725">35–42</offsets></xref><offsets xml_i="12188" xml_f="12204" txt_i="5725" txt_f="5741">). In addition, </offsets><italic><offsets xml_i="12212" xml_f="12225" txt_i="5741" txt_f="5754">Hochu-ekki-to</offsets></italic><offsets xml_i="12234" xml_f="12365" txt_i="5754" txt_f="5885"> helps to correct leukocytopenia of mice treated with anti-cancer agents and augments the resistance against bacterial infections (</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="12397" xml_f="12399" txt_i="5885" txt_f="5887">43</offsets></xref><offsets xml_i="12406" xml_f="12407" txt_i="5887" txt_f="5888">,</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="12439" xml_f="12441" txt_i="5888" txt_f="5890">44</offsets></xref><offsets xml_i="12448" xml_f="12478" txt_i="5890" txt_f="5920">). These results suggest that </offsets><italic><offsets xml_i="12486" xml_f="12499" txt_i="5920" txt_f="5933">Hochu-ekki-to</offsets></italic><offsets xml_i="12508" xml_f="12568" txt_i="5933" txt_f="5993"> may be applicable to the treatment of AD patients who have </offsets><italic><offsets xml_i="12576" xml_f="12581" txt_i="5993" txt_f="5998">Kikyo</offsets></italic><offsets xml_i="12590" xml_f="12667" txt_i="5998" txt_f="6075"> constitution. Although accumulating reports have shown clinical efficacy of </offsets><italic><offsets xml_i="12675" xml_f="12688" txt_i="6075" txt_f="6088">Hochu-ekki-to</offsets></italic><offsets xml_i="12697" xml_f="12715" txt_i="6088" txt_f="6106"> for AD patients (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="12747" xml_f="12749" txt_i="6106" txt_f="6108">13</offsets></xref><offsets xml_i="12756" xml_f="12757" txt_i="6108" txt_f="6109">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="12789" xml_f="12791" txt_i="6109" txt_f="6111">15</offsets></xref><offsets xml_i="12798" xml_f="12799" txt_i="6111" txt_f="6112">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="12831" xml_f="12833" txt_i="6112" txt_f="6114">17</offsets></xref><offsets xml_i="12840" xml_f="12841" txt_i="6114" txt_f="6115">,</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="12873" xml_f="12875" txt_i="6115" txt_f="6117">20</offsets></xref><offsets xml_i="12882" xml_f="12883" txt_i="6117" txt_f="6118">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="12915" xml_f="12917" txt_i="6118" txt_f="6120">21</offsets></xref><offsets xml_i="12924" xml_f="12925" txt_i="6120" txt_f="6121">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="12957" xml_f="12959" txt_i="6121" txt_f="6123">25</offsets></xref><offsets xml_i="12966" xml_f="12967" txt_i="6123" txt_f="6124">,</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="12999" xml_f="13001" txt_i="6124" txt_f="6126">27</offsets></xref><offsets xml_i="13008" xml_f="13009" txt_i="6126" txt_f="6127">,</offsets><xref ref-type="bibr" rid="B29 B30 B31 B32 B33"><offsets xml_i="13057" xml_f="13062" txt_i="6127" txt_f="6132">29–33</offsets></xref><offsets xml_i="13069" xml_f="13130" txt_i="6132" txt_f="6193">), no placebo-controlled study has previously been conducted.</offsets></p><p><offsets xml_i="13137" xml_f="13239" txt_i="6194" txt_f="6296">In this double-blind, placebo-controlled, randomized clinical trial, we address a question of whether </offsets><italic><offsets xml_i="13247" xml_f="13260" txt_i="6296" txt_f="6309">Hochu-ekki-to</offsets></italic><offsets xml_i="13269" xml_f="13297" txt_i="6309" txt_f="6337"> has beneficial effects for </offsets><italic><offsets xml_i="13305" xml_f="13310" txt_i="6337" txt_f="6342">Kikyo</offsets></italic><offsets xml_i="13319" xml_f="13388" txt_i="6342" txt_f="6411"> patients with AD who have been treated with conventional modalities.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="13429" xml_f="13436" txt_i="6413" txt_f="6420">Methods</offsets></title><sec><title><offsets xml_i="13456" xml_f="13469" txt_i="6421" txt_f="6434">Hochu-ekki-to</offsets></title><p><italic><offsets xml_i="13488" xml_f="13501" txt_i="6435" txt_f="6448">Hochu-ekki-to</offsets></italic><offsets xml_i="13510" xml_f="13614" txt_i="6448" txt_f="6552"> fine granules of 7.5 g contain hot water extract (6.4 g) from 10 species of medicinal plants including </offsets><italic><offsets xml_i="13622" xml_f="13635" txt_i="6552" txt_f="6565">Ginseng radix</offsets></italic><offsets xml_i="13644" xml_f="13654" txt_i="6565" txt_f="6575"> (4.0 g), </offsets><italic><offsets xml_i="13662" xml_f="13682" txt_i="6575" txt_f="6595">Atractylodis rhizoma</offsets></italic><offsets xml_i="13691" xml_f="13701" txt_i="6595" txt_f="6605"> (4.0 g), </offsets><italic><offsets xml_i="13709" xml_f="13724" txt_i="6605" txt_f="6620">Astragali radix</offsets></italic><offsets xml_i="13733" xml_f="13743" txt_i="6620" txt_f="6630"> (4.0 g), </offsets><italic><offsets xml_i="13751" xml_f="13766" txt_i="6630" txt_f="6645">Angelicae radix</offsets></italic><offsets xml_i="13775" xml_f="13785" txt_i="6645" txt_f="6655"> (3.0 g), </offsets><italic><offsets xml_i="13793" xml_f="13808" txt_i="6655" txt_f="6670">Zizyphi fructus</offsets></italic><offsets xml_i="13817" xml_f="13827" txt_i="6670" txt_f="6680"> (2.0 g), </offsets><italic><offsets xml_i="13835" xml_f="13849" txt_i="6680" txt_f="6694">Bupleuri radix</offsets></italic><offsets xml_i="13858" xml_f="13868" txt_i="6694" txt_f="6704"> (2.0 g), </offsets><italic><offsets xml_i="13876" xml_f="13894" txt_i="6704" txt_f="6722">Glycyrrhizae radix</offsets></italic><offsets xml_i="13903" xml_f="13913" txt_i="6722" txt_f="6732"> (1.5 g), </offsets><italic><offsets xml_i="13921" xml_f="13939" txt_i="6732" txt_f="6750">Zingiberis rhizoma</offsets></italic><offsets xml_i="13948" xml_f="13958" txt_i="6750" txt_f="6760"> (0.5 g), </offsets><italic><offsets xml_i="13966" xml_f="13985" txt_i="6760" txt_f="6779">Cimicifugae rhizoma</offsets></italic><offsets xml_i="13994" xml_f="14007" txt_i="6779" txt_f="6792"> (1.0 g) and </offsets><italic><offsets xml_i="14015" xml_f="14043" txt_i="6792" txt_f="6820">Aurantii nobilis Pericarpium</offsets></italic><offsets xml_i="14052" xml_f="14061" txt_i="6820" txt_f="6829"> (2.0 g).</offsets></p></sec><sec><title><offsets xml_i="14083" xml_f="14097" txt_i="6831" txt_f="6845">Assessment of </offsets><italic><offsets xml_i="14105" xml_f="14110" txt_i="6845" txt_f="6850">Kikyo</offsets></italic><offsets xml_i="14119" xml_f="14129" txt_i="6850" txt_f="6860"> Condition</offsets></title><p><italic><offsets xml_i="14148" xml_f="14153" txt_i="6861" txt_f="6866">Kikyo</offsets></italic><offsets xml_i="14162" xml_f="14234" txt_i="6866" txt_f="6938"> condition was evaluated by a questionnaire scoring system. As shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14266" xml_f="14273" txt_i="6938" txt_f="6945">Table 1</offsets></xref><offsets xml_i="14280" xml_f="14504" txt_i="6945" txt_f="7169">, the scoring questionnaire consisted of one ‘must have’ major sign (10 points) and 10 minor signs (2 points each). The patients who had the major sign and earned 18 points or more using the questionnaire were determined as </offsets><italic><offsets xml_i="14512" xml_f="14517" txt_i="7169" txt_f="7174">Kikyo</offsets></italic><offsets xml_i="14526" xml_f="14541" txt_i="7174" txt_f="7189"> constitution.
</offsets><table-wrap id="T1" position="float"><label><offsets xml_i="14585" xml_f="14593" txt_i="7189" txt_f="7197">Table 1.</offsets></label><caption><p><offsets xml_i="14613" xml_f="14664" txt_i="7197" txt_f="7248">Questionnaire scoring system for Kikyo constitution</offsets></p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"><offsets xml_i="14767" xml_f="14772" txt_i="7249" txt_f="7254">Items</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="14805" xml_f="14825" txt_i="7254" txt_f="7274">Signs and conditions</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="14858" xml_f="14864" txt_i="7274" txt_f="7280">Scores</offsets></th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><offsets xml_i="14934" xml_f="14956" txt_i="7280" txt_f="7302">Major sign (must-have)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="14989" xml_f="15030" txt_i="7303" txt_f="7344">Easy fatigability or lack of perseverance</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15063" xml_f="15065" txt_i="7345" txt_f="7347">10</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="15107" xml_f="15135" txt_i="7348" txt_f="7376">Susceptibility to infections</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15168" xml_f="15187" txt_i="7377" txt_f="7396">Susceptible to cold</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15220" xml_f="15221" txt_i="7397" txt_f="7398">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="15296" xml_f="15322" txt_i="7400" txt_f="7426">Delayed recovery from cold</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15355" xml_f="15356" txt_i="7427" txt_f="7428">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="15431" xml_f="15489" txt_i="7430" txt_f="7488">Vulnerable to other infectious diseases (herpes virus etc)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15522" xml_f="15523" txt_i="7489" txt_f="7490">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="15598" xml_f="15624" txt_i="7492" txt_f="7518">Susceptible to suppuration</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15657" xml_f="15658" txt_i="7519" txt_f="7520">2</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="15700" xml_f="15708" txt_i="7521" txt_f="7529">Anorexia</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15741" xml_f="15766" txt_i="7530" txt_f="7555">Recent very little eating</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15799" xml_f="15800" txt_i="7556" txt_f="7557">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="15875" xml_f="15888" txt_i="7559" txt_f="7572">Appetite loss</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="15921" xml_f="15922" txt_i="7573" txt_f="7574">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="15997" xml_f="16025" txt_i="7576" txt_f="7604">Easily-becoming full stomach</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16058" xml_f="16059" txt_i="7605" txt_f="7606">2</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="16134" xml_f="16154" txt_i="7608" txt_f="7628">Nahrungsverweigerung</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16187" xml_f="16188" txt_i="7629" txt_f="7630">2</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="16230" xml_f="16247" txt_i="7631" txt_f="7648">Digestive symptom</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16280" xml_f="16297" txt_i="7649" txt_f="7666">Diarrhea (laxity)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16330" xml_f="16331" txt_i="7667" txt_f="7668">2</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="16373" xml_f="16379" txt_i="7669" txt_f="7675">Others</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16412" xml_f="16450" txt_i="7676" txt_f="7714">Easy drowsiness especially after meals</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="16483" xml_f="16484" txt_i="7715" txt_f="7716">2</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="16526" xml_f="16538" txt_i="7717" txt_f="7729">Total scores</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="16604" xml_f="16606" txt_i="7731" txt_f="7733">30</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="16656" xml_f="16790" txt_i="7734" txt_f="7868">Patients who have the major sign and earn 18 points or more in this questionnaire scoring system are determined as Kikyo constitution.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec><title><offsets xml_i="16852" xml_f="16868" txt_i="7871" txt_f="7887">Study Population</offsets></title><p><offsets xml_i="16879" xml_f="16914" txt_i="7888" txt_f="7923">Patients (20–40 years of age) with </offsets><italic><offsets xml_i="16922" xml_f="16927" txt_i="7923" txt_f="7928">Kikyo</offsets></italic><offsets xml_i="16936" xml_f="17876" txt_i="7928" txt_f="8865"> constitution who fulfilled the diagnostic criteria of Japanese Dermatological Association for AD were eligible for this study. All the 91 AD patients enrolled had been treated with topical steroids (mild, strong, or very strong rank) and/or topical tacrolimus for more than 4 weeks prior to the study, and were expected to continue the same therapeutic regimen after the initiation of the study. Patients were not eligible for the study if they had been treated with only weak topical steroids (without stronger topical steroids or tacrolimus), strongest topical steroids, systemic steroids, oral suplatast tosilate, allergen desensitization therapy, or any other herbal medicines for &lt;4 weeks prior to the study. The study was approved by the responsible ethics committee and was performed in accordance with the Declaration of Helsinki and with Good Clinical Practice. An informed witnessed consent was obtained from all the patients.</offsets></p></sec><sec><title><offsets xml_i="17898" xml_f="17913" txt_i="8867" txt_f="8882">Study Protocols</offsets></title><p><offsets xml_i="17924" xml_f="18102" txt_i="8883" txt_f="9061">The study was performed in a multicenter, double blind, randomized, placebo-controlled parallel-group design. The patient number was randomly assigned a treatment code of either </offsets><italic><offsets xml_i="18110" xml_f="18123" txt_i="9061" txt_f="9074">Hochu-ekki-to</offsets></italic><offsets xml_i="18132" xml_f="18363" txt_i="9074" txt_f="9305"> or placebo using a block size of 10 (5 per each group) by an independent controller of the investigators. This code was concealed from the investigators. During trial period, patients were randomized to receive twice daily either </offsets><italic><offsets xml_i="18371" xml_f="18384" txt_i="9305" txt_f="9318">Hochu-ekki-to</offsets></italic><offsets xml_i="18393" xml_f="19167" txt_i="9318" txt_f="10092"> fine granules (Kracie Co., Ltd, Tokyo, Japan) or its inactive placebo which were indistinguishable by its appearance, odor and savor. The daily doses were 7.5 g. All patients continued their ordinary treatments such as topical steroids (other than strongest class), topical tacrolimus, emollients or oral anti-histamines. The skin severity score, amounts of topical agents, adverse effects and laboratory examination including serum IgE, lactate dehydrogenase (LDH) or eosinophil counts were monitored at pre (0-week)-, mid (12-week)- and post (24-week)-treatment. The prominent efficacy (skin severity score = 0 at the end of the study) rate and the aggravated rate (more than 50% increase of amounts of topical agents from the beginning of the study) were also evaluated.</offsets></p></sec><sec><title><offsets xml_i="19189" xml_f="19223" txt_i="10094" txt_f="10128">Assessment of Skin Severity Scores</offsets></title><p><offsets xml_i="19234" xml_f="20336" txt_i="10129" txt_f="11231">The skin severity scores of AD patients were assessed using the scoring system by the Atopic Dermatitis Severity Evaluation Committee of Japanese Dermatological Association (issued 2001). The skin severity scores were composed of eruption intensity score and affected skin area score. The body surface was divided into five sites, namely head and neck, anterior trunk, posterior trunk, upper extremities and lower extremities. The eruption intensity and affected skin area were evaluated and scored. Eruption intensity scores were evaluated using three eruption items: (i) erythema/acute papules, (ii) oozing/crusts and excoriation and (iii) lichenification/chronic papules and nodules) in the severest area scored from 0 to 3 points (0 = absent, 1 = mild, 2 = moderate, or 3 = severe) for each item in each body site. The affected skin area was also evaluated and scored in each body site as 0, 1, 2, 3 points when affected skin area was absent, less than one-third, one-third to two-third, more than two-third of each body site, respectively. Thus, the skin severity score ranges from 0 to 60 points.</offsets></p></sec><sec><title><offsets xml_i="20358" xml_f="20425" txt_i="11233" txt_f="11300">Assessment of the Dosage of Topical Steroids and Topical Tacrolimus</offsets></title><p><offsets xml_i="20436" xml_f="21077" txt_i="11301" txt_f="11942">At each patient visit, the actual amounts used of topical steroids and/or topical tacrolimus were measured by weighing the returned ointment tubes from examinees. The amount of topical agents (steroids and tacrolimus) per day was expressed as total equivalent amount (TEA) (gram arbitrary unit; gau) by multiplying potency equivalent factors as follows; weak rank steroids = × 1, mild rank steroids = × 2, strong rank steroids = × 4, very strong rank steroids = × 8, tacrolimus = × 4. Percent change of TEA to that of the beginning of the study was calculated for each patient at 12th and 24th week of treatment using the following formula;
</offsets><disp-formula><graphic xlink:href="nen003um1"></graphic></disp-formula></p></sec><sec><title><offsets xml_i="21170" xml_f="21190" txt_i="11944" txt_f="11964">Statistical Analysis</offsets></title><p><offsets xml_i="21201" xml_f="21431" txt_i="11965" txt_f="12195">Statistical analysis was performed using SAS statistical software (version 8.02; SAS Institute, Cary, NC) under the Windows XP operating system. Data were expressed as the means ± standard deviation (SD) or standard error (SE). A </offsets><italic><offsets xml_i="21439" xml_f="21440" txt_i="12195" txt_f="12196">P</offsets></italic><offsets xml_i="21449" xml_f="21589" txt_i="12196" txt_f="12333">-value of &lt;0.05 was considered to indicate statistical significance. Treatment efficacy was analyzed by comparing the difference between </offsets><italic><offsets xml_i="21597" xml_f="21610" txt_i="12333" txt_f="12346">Hochu-ekki-to</offsets></italic><offsets xml_i="21619" xml_f="21672" txt_i="12346" txt_f="12399"> and placebo control groups using unpaired Student's </offsets><italic><offsets xml_i="21680" xml_f="21681" txt_i="12399" txt_f="12400">t</offsets></italic><offsets xml_i="21690" xml_f="21719" txt_i="12400" txt_f="12429">-test or Fisher's exact test.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="21766" xml_f="21773" txt_i="12432" txt_f="12439">Results</offsets></title><sec sec-type="subjects"><title><offsets xml_i="21813" xml_f="21848" txt_i="12440" txt_f="12475">Patient Enrollment and/or Exclusion</offsets></title><p><offsets xml_i="21859" xml_f="22101" txt_i="12476" txt_f="12718">In total, 91 patients were enrolled and randomized in this trial from February to November 2002. Seven out of the initial 91 enrolled patients were excluded from subsequent analysis for the following reasons; agreement acquisition violation (</offsets><italic><offsets xml_i="22109" xml_f="22110" txt_i="12718" txt_f="12719">n</offsets></italic><offsets xml_i="22119" xml_f="22150" txt_i="12719" txt_f="12750"> = 4), eligibility violations (</offsets><italic><offsets xml_i="22158" xml_f="22159" txt_i="12750" txt_f="12751">n</offsets></italic><offsets xml_i="22168" xml_f="22217" txt_i="12751" txt_f="12800"> = 2) and failure to take trial medicine at all (</offsets><italic><offsets xml_i="22225" xml_f="22226" txt_i="12800" txt_f="12801">n</offsets></italic><offsets xml_i="22235" xml_f="22383" txt_i="12801" txt_f="12949"> = 1). Thus the number of patients who actually received medication (hereafter termed ‘full analysis set: FAS’ group) and who were analyzed was 84 (</offsets><italic><offsets xml_i="22391" xml_f="22404" txt_i="12949" txt_f="12962">Hochu-ekki-to</offsets></italic><offsets xml_i="22413" xml_f="22415" txt_i="12962" txt_f="12964">: </offsets><italic><offsets xml_i="22423" xml_f="22424" txt_i="12964" txt_f="12965">n</offsets></italic><offsets xml_i="22433" xml_f="22449" txt_i="12965" txt_f="12981"> = 40, placebo: </offsets><italic><offsets xml_i="22457" xml_f="22458" txt_i="12981" txt_f="12982">n</offsets></italic><offsets xml_i="22467" xml_f="22552" txt_i="12982" txt_f="13067"> = 44). Seventy-seven out of the 84 patients completed the 24-week treatment course (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="22582" xml_f="22588" txt_i="13067" txt_f="13073">Fig. 1</offsets></xref><offsets xml_i="22595" xml_f="22784" txt_i="13073" txt_f="13262">), including a patient in whom TAE of topical agents could not be assessed because of the insufficient descriptions on the item. There were no statistically significant differences between </offsets><italic><offsets xml_i="22792" xml_f="22805" txt_i="13262" txt_f="13275">Hochu-ekki-to</offsets></italic><offsets xml_i="22814" xml_f="22975" txt_i="13275" txt_f="13436">- and control groups in terms of age, sex, physique, duration of AD morbidity, incidence of past- or present history of other allergic or non-allergic diseases, </offsets><italic><offsets xml_i="22983" xml_f="22988" txt_i="13436" txt_f="13441">Kikyo</offsets></italic><offsets xml_i="22997" xml_f="23065" txt_i="13441" txt_f="13509"> score, skin severity score, initial TAE of topical agents per day (</offsets><ext-link ext-link-type="uri" xlink:href="http://ecam.oxfordjournals.org/cgi/content/full/nen003/DC1"><offsets xml_i="23167" xml_f="23187" txt_i="13509" txt_f="13529">Supplementary data 1</offsets></ext-link><offsets xml_i="23198" xml_f="23278" txt_i="13529" txt_f="13609">). Two out of the 7 dropped-out cases during the trial (One each in placebo and </offsets><italic><offsets xml_i="23286" xml_f="23299" txt_i="13609" txt_f="13622">Hochu-ekki-to</offsets></italic><offsets xml_i="23308" xml_f="23502" txt_i="13622" txt_f="13816"> group) were excluded because of a significant aggravation of skin eruption and occurrence of headache, respectively. Others were found unfit for further analyses (dismissal of medication etc).
</offsets><fig id="F1" position="float"><label><offsets xml_i="23539" xml_f="23548" txt_i="13816" txt_f="13825">Figure 1.</offsets></label><caption><p><offsets xml_i="23568" xml_f="23748" txt_i="13825" txt_f="14005">The chart of case enrollment and exclusion. Among the 91 enrolled AD patients, 84 patients were medicated and 77 out of the 84 patients completed full term (for 24 weeks) of trial.</offsets></p></caption><graphic xlink:href="nen003f1"></graphic></fig></p></sec><sec><title><offsets xml_i="23831" xml_f="23852" txt_i="14008" txt_f="14029">Clinical Efficacy of </offsets><italic><offsets xml_i="23860" xml_f="23873" txt_i="14029" txt_f="14042">Hochu-ekki-to</offsets></italic></title><p><offsets xml_i="23893" xml_f="23994" txt_i="14043" txt_f="14144">The overall skin severity score gradually decreased as examination went on and was slightly lower in </offsets><italic><offsets xml_i="24002" xml_f="24015" txt_i="14144" txt_f="14157">Hochu-ekki-to</offsets></italic><offsets xml_i="24024" xml_f="24097" txt_i="14157" txt_f="14230"> group (closed circle) than in placebo group (open circle) at 24th week (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="24127" xml_f="24133" txt_i="14230" txt_f="14236">Fig. 2</offsets></xref><offsets xml_i="24140" xml_f="24296" txt_i="14236" txt_f="14392">). The TEA of topical agents gradually increased in the placebo group during the trial period, whereas such increase of TEA was minimal to unchanged in the </offsets><italic><offsets xml_i="24304" xml_f="24317" txt_i="14392" txt_f="14405">Hochu-ekki-to</offsets></italic><offsets xml_i="24326" xml_f="24392" txt_i="14405" txt_f="14471"> group. The percent change of TEA at 24th week was significantly (</offsets><italic><offsets xml_i="24400" xml_f="24401" txt_i="14471" txt_f="14472">P</offsets></italic><offsets xml_i="24410" xml_f="24435" txt_i="14472" txt_f="14494"> &lt; 0.05) lower in the </offsets><italic><offsets xml_i="24443" xml_f="24456" txt_i="14494" txt_f="14507">Hochu-ekki-to</offsets></italic><offsets xml_i="24465" xml_f="24537" txt_i="14507" txt_f="14579"> group (closed circle) than in the placebo control group (open circle) (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="24567" xml_f="24573" txt_i="14579" txt_f="14585">Fig. 3</offsets></xref><offsets xml_i="24580" xml_f="24583" txt_i="14585" txt_f="14588">).
</offsets><fig id="F2" position="float"><label><offsets xml_i="24620" xml_f="24629" txt_i="14588" txt_f="14597">Figure 2.</offsets></label><caption><p><offsets xml_i="24649" xml_f="24806" txt_i="14597" txt_f="14754">The time course change of skin severity score during examination. Skin severity scores were assessed at pre-, mid (12-week)- and post (24-week)-treatment in </offsets><italic><offsets xml_i="24814" xml_f="24828" txt_i="14754" txt_f="14768">Hochu-ekki-to-</offsets></italic><offsets xml_i="24837" xml_f="24968" txt_i="14768" txt_f="14899"> (closed circle) and placebo group (open circle). Data were expressed as the mean ± SD. There is no significant difference between </offsets><italic><offsets xml_i="24976" xml_f="24990" txt_i="14899" txt_f="14913">Hochu-ekki-to-</offsets></italic><offsets xml_i="24999" xml_f="25019" txt_i="14913" txt_f="14933"> and placebo groups.</offsets></p></caption><graphic xlink:href="nen003f2"></graphic></fig><offsets xml_i="25080" xml_f="25081" txt_i="14934" txt_f="14935">
</offsets><fig id="F3" position="float"><label><offsets xml_i="25118" xml_f="25127" txt_i="14935" txt_f="14944">Figure 3.</offsets></label><caption><p><offsets xml_i="25147" xml_f="25343" txt_i="14944" txt_f="15140">The time course change of equivalent dosage of topical agent during examination. The percent changes of TEA of topical agents were assessed at pre-, mid (12-week)- and post (24-week)-treatment in </offsets><italic><offsets xml_i="25351" xml_f="25365" txt_i="15140" txt_f="15154">Hochu-ekki-to-</offsets></italic><offsets xml_i="25374" xml_f="25596" txt_i="15154" txt_f="15376"> (closed circle) and placebo group (open circle). Data were expressed as the mean ± SE. The TEA of topical agents gradually increased in the placebo group as trial went, while such increase was minimal to unchanged in the </offsets><italic><offsets xml_i="25604" xml_f="25617" txt_i="15376" txt_f="15389">Hochu-ekki-to</offsets></italic><offsets xml_i="25626" xml_f="25635" txt_i="15389" txt_f="15398"> group. *</offsets><italic><offsets xml_i="25643" xml_f="25644" txt_i="15398" txt_f="15399">P</offsets></italic><offsets xml_i="25653" xml_f="25664" txt_i="15399" txt_f="15407"> &lt; 0.05.</offsets></p></caption><graphic xlink:href="nen003f3"></graphic></fig></p><p><offsets xml_i="25732" xml_f="25738" txt_i="15409" txt_f="15415">Since </offsets><italic><offsets xml_i="25746" xml_f="25759" txt_i="15415" txt_f="15428">Hochu-ekki-to</offsets></italic><offsets xml_i="25768" xml_f="25978" txt_i="15428" txt_f="15638"> was thought to be a slow-acting herbal medicine and the present trial was relatively long-term, we wondered if a striking beneficial effect was observed in a certain population of patients by long-term use of </offsets><italic><offsets xml_i="25986" xml_f="25999" txt_i="15638" txt_f="15651">Hochu-ekki-to</offsets></italic><offsets xml_i="26008" xml_f="26205" txt_i="15651" txt_f="15848">. Therefore, we analyzed a prominent efficacy rate, the rate of patients whose skin severity score became 0 at the end of the study. The prominent efficacy rate was indeed moderately higher in the </offsets><italic><offsets xml_i="26213" xml_f="26226" txt_i="15848" txt_f="15861">Hochu-ekki-to</offsets></italic><offsets xml_i="26235" xml_f="26347" txt_i="15861" txt_f="15973"> group (19%; 7 of 37) than in the placebo group (5%; 2 of 40), although there was not a significant difference (</offsets><italic><offsets xml_i="26355" xml_f="26356" txt_i="15973" txt_f="15974">P</offsets></italic><offsets xml_i="26365" xml_f="26552" txt_i="15974" txt_f="16161"> = 0.06). Furthermore, the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study, was significantly lower in the </offsets><italic><offsets xml_i="26560" xml_f="26573" txt_i="16161" txt_f="16174">Hochu-ekki-to</offsets></italic><offsets xml_i="26582" xml_f="26645" txt_i="16174" txt_f="16237"> group (3%; 1 of 37) than in the placebo group (18%; 7 of 39) (</offsets><italic><offsets xml_i="26653" xml_f="26654" txt_i="16237" txt_f="16238">P</offsets></italic><offsets xml_i="26663" xml_f="26808" txt_i="16238" txt_f="16380"> &lt; 0.05). There was no significant difference in the serum IgE, LDH, or eosinophil counts in peripheral blood in both groups (data not shown).</offsets></p></sec><sec><title><offsets xml_i="26830" xml_f="26877" txt_i="16382" txt_f="16429">Adverse Events and Abnormal Laboratory Findings</offsets></title><p><offsets xml_i="26888" xml_f="27048" txt_i="16430" txt_f="16590">The adverse events, including those of unclear causality with treatment using tested agents, were observed in 13 of 40 patients (32.5%, total 33 events) in the </offsets><italic><offsets xml_i="27056" xml_f="27069" txt_i="16590" txt_f="16603">Hochu-ekki-to</offsets></italic><offsets xml_i="27078" xml_f="27286" txt_i="16603" txt_f="16811"> group and in 12 of 44 patients (27.3%, total 20 events) in the placebo group. All the adverse events were moderate symptoms such as nausea and diarrhea etc or slight increase or decrease of laboratory data (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="27318" xml_f="27325" txt_i="16811" txt_f="16818">Table 2</offsets></xref><offsets xml_i="27332" xml_f="27335" txt_i="16818" txt_f="16821">).
</offsets><table-wrap id="T2" position="float"><label><offsets xml_i="27379" xml_f="27387" txt_i="16821" txt_f="16829">Table 2.</offsets></label><caption><p><offsets xml_i="27407" xml_f="27422" txt_i="16829" txt_f="16844">Adverse effects</offsets></p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1"><offsets xml_i="27558" xml_f="27598" txt_i="16845" txt_f="16885">The number of cases with adverse effects</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="27631" xml_f="27752" txt_i="16885" txt_f="17006">Adverse effects (the number of cases if not one), including those of unclear causality with treatment using tested agents</offsets></th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><offsets xml_i="27822" xml_f="27841" txt_i="17006" txt_f="17025">Hochu-ekki-to group</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27874" xml_f="27887" txt_i="17026" txt_f="17039">13/40 (32.5%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27920" xml_f="27938" txt_i="17040" txt_f="17058">Symptoms: nausea (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="27969" xml_f="27970" txt_i="17058" txt_f="17059">2</offsets></xref><offsets xml_i="27977" xml_f="27990" txt_i="17059" txt_f="17072">), diarrhea (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="28021" xml_f="28022" txt_i="17072" txt_f="17073">2</offsets></xref><offsets xml_i="28029" xml_f="28052" txt_i="17073" txt_f="17096">), stomach discomfort (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="28083" xml_f="28084" txt_i="17096" txt_f="17097">2</offsets></xref><offsets xml_i="28091" xml_f="28302" txt_i="17097" txt_f="17308">), enlarged feeling of abdomen, epigastralgia, anorexia, loose stools, right hypochondrium pain, malaise, dizziness, headache, light-headed feeling, rhinitis, acne pustulosa, feverish thirstiness, dental caries.</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="28410" xml_f="28441" txt_i="17311" txt_f="17342">Laboratory data: eosinophilia (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="28472" xml_f="28473" txt_i="17342" txt_f="17343">3</offsets></xref><offsets xml_i="28480" xml_f="28544" txt_i="17343" txt_f="17407">), GPT elevation, IgE elevation, BUN decline, serum K elevation.</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28586" xml_f="28607" txt_i="17408" txt_f="17429">Placebo-control group</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28640" xml_f="28653" txt_i="17430" txt_f="17443">12/44 (27.3%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28686" xml_f="28714" txt_i="17444" txt_f="17472">Symptoms: ovarian disorder (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="28745" xml_f="28746" txt_i="17472" txt_f="17473">2</offsets></xref><offsets xml_i="28753" xml_f="28840" txt_i="17473" txt_f="17560">), diarrhea, epigastric discomfort, anorexia, malaise, hives, insomnia, feverish limbs.</offsets></td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="28948" xml_f="28979" txt_i="17563" txt_f="17594">Laboratory data: eosinophilia (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="29010" xml_f="29011" txt_i="17594" txt_f="17595">4</offsets></xref><offsets xml_i="29018" xml_f="29036" txt_i="17595" txt_f="17613">), LDH elevation (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="29067" xml_f="29068" txt_i="17613" txt_f="17614">2</offsets></xref><offsets xml_i="29075" xml_f="29093" txt_i="17614" txt_f="17632">), GOT elevation (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="29124" xml_f="29125" txt_i="17632" txt_f="17633">2</offsets></xref><offsets xml_i="29132" xml_f="29200" txt_i="17633" txt_f="17701">), γ-GTP elevation, serum total protein decline, hemoglobin decline.</offsets></td></tr></tbody></table></table-wrap></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="29289" xml_f="29299" txt_i="17705" txt_f="17715">Discussion</offsets></title><p><offsets xml_i="29310" xml_f="29377" txt_i="17716" txt_f="17783">The present study demonstrates that 24-week oral administration of </offsets><italic><offsets xml_i="29385" xml_f="29398" txt_i="17783" txt_f="17796">Hochu-ekki-to</offsets></italic><offsets xml_i="29407" xml_f="29467" txt_i="17796" txt_f="17856"> has a substantial benefit over placebo in the treatment of </offsets><italic><offsets xml_i="29475" xml_f="29480" txt_i="17856" txt_f="17861">Kikyo</offsets></italic><offsets xml_i="29489" xml_f="29530" txt_i="17861" txt_f="17902"> patients with AD. The administration of </offsets><italic><offsets xml_i="29538" xml_f="29551" txt_i="17902" txt_f="17915">Hochu-ekki-to</offsets></italic><offsets xml_i="29560" xml_f="30013" txt_i="17915" txt_f="18368"> significantly reduces dosage of topical steroids and/or tacrolimus, compared with placebo, although there was no significant difference in the mean skin severity scores between both groups. These results indicate that the patients in the placebo group need significantly more topical steroids and/or tacrolimus in order to control their skin conditions. In keeping with this notion, the post-treatment prominent efficacy rate tends to be higher in the </offsets><italic><offsets xml_i="30021" xml_f="30034" txt_i="18368" txt_f="18381">Hochu-ekki-to</offsets></italic><offsets xml_i="30043" xml_f="30141" txt_i="18381" txt_f="18479"> group than in the placebo group. In contrast, the aggravated rate was significantly lower in the </offsets><italic><offsets xml_i="30149" xml_f="30162" txt_i="18479" txt_f="18492">Hochu-ekki-to</offsets></italic><offsets xml_i="30171" xml_f="30251" txt_i="18492" txt_f="18572"> group than in the placebo group. It was surprising that 19% of patients in the </offsets><italic><offsets xml_i="30259" xml_f="30272" txt_i="18572" txt_f="18585">Hochu-ekki-to</offsets></italic><offsets xml_i="30281" xml_f="30533" txt_i="18585" txt_f="18837"> group were devoid of skin eruption after the 24-week treatment. Considering the long-term history of the majority of the 7 ‘eruption-free’ patients (10–34 years, mean ± SD: 21.9 ± 8.0), this marked improvement would indicate the beneficial effects of </offsets><italic><offsets xml_i="30541" xml_f="30554" txt_i="18837" txt_f="18850">Hochu-ekki-to</offsets></italic><offsets xml_i="30563" xml_f="30674" txt_i="18850" txt_f="18961">, as ‘spontaneous’ healing was not likely to take place in those severe AD patients during the course of trial.</offsets></p><p><italic><offsets xml_i="30689" xml_f="30702" txt_i="18962" txt_f="18975">Hochu-ekki-to</offsets></italic><offsets xml_i="30711" xml_f="31107" txt_i="18975" txt_f="19371">, however, did not seem to be effective for all the AD patients in this trial. Individual difference of intestinal flora has been proposed to be one of the major reasons for such disparity of the efficiency of Kampo therapy. It is because active components of orally administered herbal drugs are known to be assimilated through the intestinal mucosa under the influence of the intestinal flora (</offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="31139" xml_f="31141" txt_i="19371" txt_f="19373">45</offsets></xref><offsets xml_i="31148" xml_f="31580" txt_i="19373" txt_f="19805">). Although we generally advise patients to choose traditional Japanese diet in usual Kampo treatment as intestinal flora can be affected by daily diet, we have avoided intensive intervention during this trial period, assuming that such intervention could be a considerable stress for certain patients and could significantly influence their clinical course of skin symptoms by increasing itch sensation etc. The clinical action of </offsets><italic><offsets xml_i="31588" xml_f="31601" txt_i="19805" txt_f="19818">Hochu-ekki-to</offsets></italic><offsets xml_i="31610" xml_f="31889" txt_i="19818" txt_f="20097"> appears to be rather mild and limited; however, the present study clearly demonstrates an add-on beneficial effect of this herbal drug over the conventional treatments. Kampo herbal drugs are broadly classified into two categories, immediate acting- and slow acting ones. Since </offsets><italic><offsets xml_i="31897" xml_f="31910" txt_i="20097" txt_f="20110">Hochu-ekki-to</offsets></italic><offsets xml_i="31919" xml_f="31988" txt_i="20110" txt_f="20179"> is considered to work in the latter manner, supporting the inactive </offsets><italic><offsets xml_i="31996" xml_f="32001" txt_i="20179" txt_f="20184">Kikyo</offsets></italic><italic><offsets xml_i="32018" xml_f="32031" txt_i="20184" txt_f="20197">Hochu-ekki-to</offsets></italic><offsets xml_i="32040" xml_f="32215" txt_i="20197" txt_f="20372">. The significant clinical benefits indeed appeared at 24th week rather than 12th week, as shown by the reduction of TEA of topical agents and of the reduced aggravated rates.</offsets></p><p><offsets xml_i="32222" xml_f="32287" txt_i="20373" txt_f="20438">Kampo herbal drugs are usually prescribed according to patient's </offsets><italic><offsets xml_i="32295" xml_f="32298" txt_i="20438" txt_f="20441">Sho</offsets></italic><offsets xml_i="32307" xml_f="32341" txt_i="20441" txt_f="20475"> (constitution/condition) such as </offsets><italic><offsets xml_i="32349" xml_f="32352" txt_i="20475" txt_f="20478">Yin</offsets></italic><offsets xml_i="32361" xml_f="32379" txt_i="20478" txt_f="20496"> (negativity) and </offsets><italic><offsets xml_i="32387" xml_f="32391" txt_i="20496" txt_f="20500">Yang</offsets></italic><offsets xml_i="32400" xml_f="32417" txt_i="20500" txt_f="20517"> (positivity) or </offsets><italic><offsets xml_i="32425" xml_f="32428" txt_i="20517" txt_f="20520">Kyo</offsets></italic><offsets xml_i="32437" xml_f="32455" txt_i="20520" txt_f="20538"> (deficiency) and </offsets><italic><offsets xml_i="32463" xml_f="32468" txt_i="20538" txt_f="20543">Jitsu</offsets></italic><offsets xml_i="32477" xml_f="32531" txt_i="20543" txt_f="20597"> (fullness) and to target components to treat such as </offsets><italic><offsets xml_i="32539" xml_f="32541" txt_i="20597" txt_f="20599">Ki</offsets></italic><offsets xml_i="32550" xml_f="32582" txt_i="20599" txt_f="20631"> (energy, spirit and function), </offsets><italic><offsets xml_i="32590" xml_f="32595" txt_i="20631" txt_f="20636">Ketsu</offsets></italic><offsets xml_i="32604" xml_f="32628" txt_i="20636" txt_f="20660"> (blood and organs) and </offsets><italic><offsets xml_i="32636" xml_f="32639" txt_i="20660" txt_f="20663">Sui</offsets></italic><offsets xml_i="32648" xml_f="32734" txt_i="20663" txt_f="20749"> (fluid), all of which are considered to be basic components constituting human body. </offsets><italic><offsets xml_i="32742" xml_f="32755" txt_i="20749" txt_f="20762">Hochu-ekki-to</offsets></italic><offsets xml_i="32764" xml_f="32795" txt_i="20762" txt_f="20793"> is recommended to be used for </offsets><italic><offsets xml_i="32803" xml_f="32808" txt_i="20793" txt_f="20798">Kikyo</offsets></italic><offsets xml_i="32817" xml_f="32899" txt_i="20798" txt_f="20880"> condition, a state of functional deficiency. In our trial, only AD patients with </offsets><italic><offsets xml_i="32907" xml_f="32912" txt_i="20880" txt_f="20885">Kikyo</offsets></italic><offsets xml_i="32921" xml_f="33092" txt_i="20885" txt_f="21056"> constitution were selected eligible by using the questionnaire scoring system. This selection may favorably contribute to carve in relief of the clinical significance of </offsets><italic><offsets xml_i="33100" xml_f="33113" txt_i="21056" txt_f="21069">Hochu-ekki-to</offsets></italic><offsets xml_i="33122" xml_f="33235" txt_i="21069" txt_f="21182"> over placebo, thus it remains to be tested if the herbal drug has such beneficial effect on AD patients without </offsets><italic><offsets xml_i="33243" xml_f="33248" txt_i="21182" txt_f="21187">Kikyo</offsets></italic><offsets xml_i="33257" xml_f="33271" txt_i="21187" txt_f="21201"> constitution.</offsets></p><p><offsets xml_i="33278" xml_f="33386" txt_i="21202" txt_f="21310">Although considerable attention has been paid on traditional herbal medicines as a treatment option for AD (</offsets><xref ref-type="bibr" rid="B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33"><offsets xml_i="33498" xml_f="33503" txt_i="21310" txt_f="21315">13–33</offsets></xref><offsets xml_i="33510" xml_f="33641" txt_i="21315" txt_f="21446">), there are only a few reports examining their efficacy in a randomized, double blind manner, as reviewed by Armstrong and Ernst (</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="33673" xml_f="33675" txt_i="21446" txt_f="21448">46</offsets></xref><offsets xml_i="33682" xml_f="33693" txt_i="21448" txt_f="21459">). Sheehan </offsets><italic><offsets xml_i="33701" xml_f="33707" txt_i="21459" txt_f="21465">et al.</offsets></italic><offsets xml_i="33716" xml_f="33718" txt_i="21465" txt_f="21467"> (</offsets><xref ref-type="bibr" rid="B47 B48 B49"><offsets xml_i="33758" xml_f="33763" txt_i="21467" txt_f="21472">47–49</offsets></xref><offsets xml_i="33770" xml_f="33998" txt_i="21472" txt_f="21700">) have reported the usefulness of the composite herbs of Zemaphyte® in a randomized, double blind cross-over trial, where it was shown that the Zemaphyte's composite herbs possess anti-inflammatory and anti-congestive function (</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="34030" xml_f="34032" txt_i="21700" txt_f="21702">48</offsets></xref><offsets xml_i="34039" xml_f="34078" txt_i="21702" txt_f="21741">). However, a subsequent trial by Fung </offsets><italic><offsets xml_i="34086" xml_f="34092" txt_i="21741" txt_f="21747">et al.</offsets></italic><offsets xml_i="34101" xml_f="34103" txt_i="21747" txt_f="21749"> (</offsets><xref ref-type="bibr" rid="B50"><offsets xml_i="34135" xml_f="34137" txt_i="21749" txt_f="21751">50</offsets></xref><offsets xml_i="34144" xml_f="34293" txt_i="21751" txt_f="21900">) failed to confirm its superiority over placebo. Although efficacies of herbal medicines are now being recognized even outside the Asian countries (</offsets><xref ref-type="bibr" rid="B51"><offsets xml_i="34325" xml_f="34327" txt_i="21900" txt_f="21902">51</offsets></xref><offsets xml_i="34334" xml_f="34502" txt_i="21902" txt_f="22070">), there has been no report of double-blind, randomized and placebo-controlled trial of herbal drugs as treatment for AD other than Zemaphyte® before the present study.</offsets></p><p><offsets xml_i="34509" xml_f="34550" txt_i="22071" txt_f="22112">In conclusion, our results indicate that </offsets><italic><offsets xml_i="34558" xml_f="34571" txt_i="22112" txt_f="22125">Hochu-ekki-to</offsets></italic><offsets xml_i="34580" xml_f="34632" txt_i="22125" txt_f="22177"> is a useful adjunct to conventional treatments for </offsets><italic><offsets xml_i="34640" xml_f="34645" txt_i="22177" txt_f="22182">Kikyo</offsets></italic><offsets xml_i="34654" xml_f="34795" txt_i="22182" txt_f="22323"> patients with AD. We contend that it can reduce the dosage of topical steroids and tacrolimus without aggravating the clinical course of AD.</offsets></p></sec><sec><title><offsets xml_i="34817" xml_f="34835" txt_i="22325" txt_f="22343">Supplementary Data</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://ecam.oxfordjournals.org/cgi/content/full/nen003/DC1"><offsets xml_i="34948" xml_f="34966" txt_i="22344" txt_f="22362">Supplementary data</offsets></ext-link><offsets xml_i="34977" xml_f="34995" txt_i="22362" txt_f="22380"> are available at </offsets><italic><offsets xml_i="35003" xml_f="35007" txt_i="22380" txt_f="22384">eCAM</offsets></italic><offsets xml_i="35016" xml_f="35024" txt_i="22384" txt_f="22392"> online.</offsets></p></sec><offsets xml_i="35034" xml_f="35041" txt_i="22394" txt_f="22401">
      </offsets><sec sec-type="supplementary-material"><offsets xml_i="35080" xml_f="35090" txt_i="22401" txt_f="22411">
         </offsets><title><offsets xml_i="35097" xml_f="35119" txt_i="22411" txt_f="22433">Supplementary Material</offsets></title><offsets xml_i="35127" xml_f="35137" txt_i="22434" txt_f="22444">
         </offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="35198" xml_f="35211" txt_i="22444" txt_f="22457">
            </offsets><caption><offsets xml_i="35220" xml_f="35236" txt_i="22457" txt_f="22473">
               </offsets><title><offsets xml_i="35243" xml_f="35263" txt_i="22473" txt_f="22493">[Supplementary Data]</offsets></title><offsets xml_i="35271" xml_f="35284" txt_i="22494" txt_f="22507">
            </offsets></caption><offsets xml_i="35294" xml_f="35307" txt_i="22507" txt_f="22520">
            </offsets><media mimetype="text" mime-subtype="html" xlink:href="nen003_index.html"></media><offsets xml_i="35389" xml_f="35402" txt_i="22520" txt_f="22533">
            </offsets><media xlink:role="associated-file" mimetype="text" mime-subtype="plain" xlink:href="nen003_ecam-07-0203-File007.JPG"></media><offsets xml_i="35528" xml_f="35538" txt_i="22533" txt_f="22543">
         </offsets></supplementary-material><offsets xml_i="35563" xml_f="35570" txt_i="22543" txt_f="22550">
      </offsets></sec><offsets xml_i="35576" xml_f="35580" txt_i="22551" txt_f="22555">
   </offsets></body><back><ack><title>Acknowledgements</title><p>This work was sponsored by Kracie Ltd (Tokyo, Japan). We are indebted to participating investigators in the Study; Yamano Dermatological Clinic: T. Yamano; Tanizaki Dermatological Clinic: Y. Tanizaki; Shimizu Dermatological Clinic: N. Shimizu; Iriki Dermatological Clinic: A. Iriki; Higashihie Dermatological Clinic: A. Nishie; Haradoi Hospital; H. Ikematsu, K. Hayashida; Department of Dermatology, Osaka City University Graduate School of Medicine: H. Teramae, H. Kutsuna, K. Yoshida; Osaka City General Hospital: S. Suzuki, K. Nakano; Osaka City Juso Hospital: S. Kuniyuki, Hoshigaoka Koseinenkin Hospital: H. Kato, C. Yasunaga; Izumi City Hospital: K. Yoshioka, T. Murakami. In addition, we thank Takuya Kawakita, Hide-itiro Ogasawara, Kazunori Yamamoto, Ai Iwabuti, Yuki Kubo and Katsutaka Sakai of Kracie Ltd. (Tokyo, Japan).</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanifin</surname><given-names>JM</given-names></name><name><surname>Rajka</surname><given-names>G</given-names></name></person-group><article-title>Diagnostic features of atopic dermatitis</article-title><source>Acta Derm Venereol <italic>(Stockholm) Suppl</italic></source><year>1980</year><volume>92</volume><fpage>44</fpage><lpage>7</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furue</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>F</given-names></name><name><surname>Hide</surname><given-names>M</given-names></name><name><surname>Takehara</surname><given-names>K</given-names></name></person-group><article-title>Guidelines for therapy for atopic dermatitis 2004</article-title><source>Jpn J Dermatol</source><year>2004</year><volume>114</volume><fpage>135</fpage><lpage>42</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoare</surname><given-names>C</given-names></name><name><surname>Li Wan Po</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>H</given-names></name></person-group><article-title>Systematic review of treatments for atopic eczema</article-title><source>Health Technol Assess</source><year>2000</year><volume>4</volume><fpage>1</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">11134919</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>HC</given-names></name></person-group><article-title>Is the prevalence of atopic dermatitis increasing?</article-title><source>Clin Exp Dermatol</source><year>1992</year><volume>17</volume><fpage>385</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">1486704</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>H</given-names></name><name><surname>Robertson</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Aït-Khaled</surname><given-names>N</given-names></name><name><surname>Anabwani</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood</article-title><source>J Allergy Clin Immunol</source><year>1999</year><volume>103</volume><fpage>125</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">9893196</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>H</given-names></name></person-group><article-title>Increase of adult atopic dermatitis (AD) in recent Japan</article-title><source>Environ Dermatol</source><year>2000</year><volume>7</volume><fpage>133</fpage><lpage>6</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeki</surname><given-names>H</given-names></name><name><surname>Tsunemi</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Kagami</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Ohmatsu</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Prevalence of atopic dermatitis determined by clinical examination in Japanese adults</article-title><source>J Dermatol</source><year>2006</year><volume>33</volume><fpage>817</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17074002</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>C</given-names></name><name><surname>Luger</surname><given-names>T</given-names></name><name><surname>Abeck</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>R</given-names></name><name><surname>Graham-Brown</surname><given-names>RA</given-names></name><name><surname>De Prost</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>ICCAD II faculty. International consensus conference on atopic dermatitis II (ICCAD II): clinical update and current treatment strategies</article-title><source>Br J Dermatol</source><year>2003</year><volume>148</volume><issue>Suppl 63</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">12694268</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarous</surname><given-names>MC</given-names></name><name><surname>Kerdel</surname><given-names>FA</given-names></name></person-group><article-title>Topical tacrolimus protopic</article-title><source>Drugs Today</source><year>2002</year><volume>38</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12532181</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitamo</surname><given-names>S</given-names></name><name><surname>Rissanen</surname><given-names>J</given-names></name><name><surname>Remitz</surname><given-names>A</given-names></name><name><surname>Granlund</surname><given-names>H</given-names></name><name><surname>Erkko</surname><given-names>P</given-names></name><name><surname>Elg</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial</article-title><source>J Invest Dermatol</source><year>1998</year><volume>111</volume><fpage>396</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9740230</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soter</surname><given-names>NA</given-names></name><name><surname>Fleischer</surname><given-names>AB</given-names><suffix>Jr</suffix></name><name><surname>Webster</surname><given-names>GF</given-names></name><name><surname>Monroe</surname><given-names>E</given-names></name><name><surname>Lawrence</surname><given-names>I</given-names></name></person-group><article-title>Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety</article-title><source>J Am Acad Dermatol</source><year>2001</year><volume>44</volume><issue>Suppl 1</issue><fpage>S39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">11145794</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charman</surname><given-names>CR</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Williams</surname><given-names>HC</given-names></name></person-group><article-title>Topical corticosteroid phobia in patients with atopic eczema</article-title><source>Br J Dermatol</source><year>2000</year><volume>142</volume><fpage>931</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10809850</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Asai</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name></person-group><article-title>Experiences of therapy for skin disease by Japanese herbal medicine</article-title><source>Kampo Med</source><year>1981</year><volume>5</volume><fpage>9</fpage><lpage>11</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiguchi</surname><given-names>Y</given-names></name><name><surname>Horiguchi</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Oguchi</surname><given-names>M</given-names></name><name><surname>Ozaki</surname><given-names>M</given-names></name></person-group><article-title>Effect of Saiko-seikan-to on atopic dermatitis</article-title><source>Hifuka kiyo</source><year>1983</year><volume>78</volume><fpage>145</fpage><lpage>50</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>I</given-names></name></person-group><article-title>Clinical dermatology 7, eczema and dermatitis II, atopic dermatitis</article-title><source>The Kampo</source><year>1986</year><volume>4</volume><fpage>2</fpage><lpage>17</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninomiya</surname><given-names>F</given-names></name></person-group><article-title>Kampo for adult atopic dermatitis</article-title><source>Gendai Toyo igaku</source><year>1988</year><volume>9</volume><fpage>162</fpage><lpage>5</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Tanii</surname><given-names>T</given-names></name><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name></person-group><article-title>Kampo therapies for atopic dermatitis: the effectiveness of Hochu-ekki-to</article-title><source>Nishinihon Hifu</source><year>1989</year><volume>51</volume><fpage>1003</fpage><lpage>13</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morohashi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name></person-group><article-title>Kampo medicine for atopic dermatitis</article-title><source>Allerugi no Rinsho</source><year>1989</year><volume>9</volume><fpage>711</fpage><lpage>4</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Tsujii</surname><given-names>Y</given-names></name><name><surname>Yamagami</surname><given-names>N</given-names></name><name><surname>Aragane</surname><given-names>Y</given-names></name><name><surname>Saeki</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Clinical effectiveness of Sairei-to for atopic dermatitis</article-title><source>Nishinihon Hifu</source><year>1990</year><volume>52</volume><fpage>1202</fpage><lpage>7</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Tsujimoto</surname><given-names>Y</given-names></name><name><surname>Iikura</surname><given-names>Y</given-names></name><name><surname>Kamiya</surname><given-names>A</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Kurashige</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Study of clinical efficacy of Hochu-ekki-to for child patients with atopic dermatitis</article-title><source>Rinsho Kenkyu</source><year>1993</year><volume>70</volume><fpage>4012</fpage><lpage>21</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>T</given-names></name></person-group><person-group person-group-type="editor"><collab>Dermatological Oriental Medicine Study Group (eds)</collab></person-group><article-title>Kampo therapy in dermatology</article-title><source>State of Herb Treatments in Dermatology</source><year>1994;</year><volume>5</volume><publisher-loc>Tokyo</publisher-loc><publisher-name>Igakushoin</publisher-name><fpage>3</fpage><lpage>21</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>K</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shibahara</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name></person-group><article-title>Four cases report of atopic dermatitis successfully treated with Tokaku-joki-to</article-title><source>Jpn J Oriental Med</source><year>1995</year><volume>46</volume><fpage>45</fpage><lpage>54</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>O</given-names></name><name><surname>Terasawa</surname><given-names>K</given-names></name></person-group><article-title>Unkei-to related Kampo formulas for atopic dermatitis</article-title><source>Curr Ther</source><year>1995</year><volume>13</volume><fpage>2041</fpage><lpage>4</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujinaga</surname><given-names>H</given-names></name><name><surname>Terasawa</surname><given-names>K</given-names></name></person-group><article-title>A case with atopic dermatitis in whom Keigai-rengyo-to related formula was effective</article-title><source>Curr Ther</source><year>1996</year><volume>14</volume><fpage>513</fpage><lpage>5</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>I</given-names></name></person-group><person-group person-group-type="editor"><collab>Dermatological Oriental Medicine Study Group (eds)</collab></person-group><article-title>Japanese herb treatments of adult atopic dermatitis by diet and Japanese herb remedy—evaluation of disappearance of disease phases</article-title><source>State of Herb Treatments in Dermatology</source><year>1997</year><volume>9</volume><publisher-loc>Tokyo</publisher-loc><publisher-name>Sogoigaku Co.;</publisher-name><fpage>63</fpage><lpage>77</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>H</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Shintani</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Terasawa</surname><given-names>K</given-names></name></person-group><article-title>On the indication of Shishi-zai</article-title><source>Jpn J Oriental Med</source><year>1997</year><volume>48</volume><fpage>225</fpage><lpage>32</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsuaki</surname><given-names>M</given-names></name></person-group><article-title>Kampo therapy for eczema and dermatitis</article-title><source>Derma</source><year>1998</year><volume>11</volume><fpage>27</fpage><lpage>32</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninomiya</surname><given-names>F</given-names></name></person-group><article-title>Experience of Shishi-hakuhi-to in the treatment of dermatitis</article-title><source>Kampo kenkyu</source><year>1999</year><volume>326</volume><fpage>38</fpage><lpage>42</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>M</given-names></name></person-group><person-group person-group-type="editor"><collab>Dermatological Oriental Medicine Study Group (eds)</collab></person-group><article-title>Combination therapy with diet and traditional Japanese medicine for intractable adult atopic dermatitis—Interpretation of dietary influence</article-title><source>State of Herb Treatments in Dermatology</source><year>1999</year><volume>10</volume><publisher-loc>Tokyo</publisher-loc><publisher-name>Kyowa Kikaku Tsushin</publisher-name><fpage>35</fpage><lpage>42</lpage><comment>(in Japanese)</comment></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Teramae</surname><given-names>H</given-names></name><name><surname>Kutsuna</surname><given-names>H</given-names></name><name><surname>Ueoku</surname><given-names>S</given-names></name><name><surname>Onoyama</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety</article-title><source>Drugs Exp Clin Res</source><year>2004</year><volume>30</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15700746</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Teramae</surname><given-names>H</given-names></name><name><surname>Kutsuna</surname><given-names>H</given-names></name><name><surname>Ueoku</surname><given-names>S</given-names></name><name><surname>Onoyama</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>The effects of Hochu-ekki-to in patients with atopic dermatitis resistant to conventional treatment</article-title><source>Int J Tissue React</source><year>2004</year><volume>26</volume><fpage>113</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15648444</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Kutsuna</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name></person-group><article-title>An alternative approach to atopic dermatitis: part I—case-series presentation</article-title><source>Evid based Complement Alternat Med</source><year>2004</year><volume>1</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15257326</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Kutsuna</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name></person-group><article-title>An alternative approach to atopic dermatitis: part II—Summary of cases and discussion</article-title><source>Evid based Complement Alternat Med</source><year>2004</year><volume>1</volume><fpage>145</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15480440</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>K</given-names></name></person-group><article-title>Evidence-based reconstruction of Kampo medicine: part II—the concept of Sho</article-title><source>Evid based Complement Alternat Med</source><year>2004</year><volume>1</volume><fpage>119</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15480437</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Kishihara</surname><given-names>K</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Takimoto</surname><given-names>H</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group><article-title>Suppression of IgE production in mice treated with a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to)</article-title><source>Immunopharmacology</source><year>1997</year><volume>36</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">9129999</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Kishihara</surname><given-names>K</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group><article-title>Effect of a traditional Chinese medicine, Bu-Zhong-Yi-Qi-Tang on the protection against an oral infection with Listeria monocytogenes</article-title><source>Immunopharmacology</source><year>1998</year><volume>39</volume><fpage>215</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9754907</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>E</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>C</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Terasawa</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Effect of Kampo medicines on IgE-mediated biphasic cutaneous reaction in mice</article-title><source>J Trad Med</source><year>1998</year><volume>15</volume><fpage>100</fpage><lpage>8</lpage></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group><article-title>Immunopharmacological effects of Hochu-ekki-to and its clinical application</article-title><source>Prog Med</source><year>1998</year><volume>18</volume><fpage>801</fpage><lpage>7</lpage></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group><article-title>Inhibition of eosinophil infiltration into the mouse peritoneal cavity by a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to)</article-title><source>Immunopharmacol Immunotoxicol</source><year>1999</year><volume>21</volume><fpage>125</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10084334</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimitsu</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Kawauchi</surname><given-names>H</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Yoshikai</surname><given-names>Y</given-names></name></person-group><article-title>Dichotomous effect of a traditional Japanese medicine, bu-zhong-yi-qi-tang on allergic asthma in mice</article-title><source>Int Immunopharmacol</source><year>2001</year><volume>1</volume><fpage>857</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11379041</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Kutsuna</surname><given-names>H</given-names></name><name><surname>Teramae</surname><given-names>H</given-names></name><name><surname>Ueoku</surname><given-names>S</given-names></name><name><surname>Onoyama</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Hochu-ekki-to suppresses development of dermatitis and elevation of serum IgE level in NC/Nga mice</article-title><source>Drugs Exp Clin Res</source><year>2003</year><volume>29</volume><fpage>81</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12951838</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>XK</given-names></name><name><surname>Fuseda</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Inagaki</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>H</given-names></name></person-group><article-title>Kampo medicines for mite antigen-induced allergic dermatitis in NC/Nga Mice</article-title><source>Evid Based Complement Alternat Med</source><year>2005</year><volume>2</volume><fpage>191</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15937560</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Takimoto</surname><given-names>H</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Yoshikai</surname><given-names>Y</given-names></name><name><surname>Matsuzaki</surname><given-names>G</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group><article-title>Effect of a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to) on the protection against Listeria monocytogenes infection in mice</article-title><source>Immunopharmacol Immunotoxicol</source><year>1992</year><volume>14</volume><fpage>383</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">1517527</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>M</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Kumazawa</surname><given-names>Y</given-names></name><name><surname>Takimoto</surname><given-names>H</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name></person-group><article-title>Accelerated recovery from cyclophosphamide-induced leukopenia in mice administered a Japanese ethical herbal drug, Hochu-ekki-to</article-title><source>Immunopharmacology</source><year>1999</year><volume>44</volume><fpage>223</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10598879</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>ZM</given-names></name><name><surname>Yan</surname><given-names>MZ</given-names></name><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Xiong</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Metabolism of constituents in Huangqin-tang, a prescription in traditional Chinese medicine, by human intestinal flora</article-title><source>Biol Pharm Bull</source><year>2002</year><volume>25</volume><fpage>558</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12033492</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>NC</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>The treatment of eczema with Chinese herbs: a systemic review of randomized clinical trials</article-title><source>Br J Clin Pharmacol</source><year>1999</year><volume>48</volume><fpage>262</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10417508</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>MP</given-names></name><name><surname>Rustin</surname><given-names>MH</given-names></name><name><surname>Atherton</surname><given-names>DJ</given-names></name><name><surname>Buckley</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>DJ</given-names></name><name><surname>Brostoff</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis</article-title><source>Lancet</source><year>1992</year><volume>340</volume><fpage>13</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1351600</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>MP</given-names></name><name><surname>Atherton</surname><given-names>DJ</given-names></name></person-group><article-title>A controlled trial of traditional Chinese medicine plants in widespread non-exudative atopic eczema</article-title><source>Br J Dermatol</source><year>1992</year><volume>126</volume><fpage>179</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">1536784</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>MP</given-names></name><name><surname>Atherton</surname><given-names>DJ</given-names></name></person-group><article-title>One-year follow up of children treated with Chinese medicinal herbs for atopic eczema</article-title><source>Br J Dermatol</source><year>1994</year><volume>130</volume><fpage>488</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">8186115</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>AY</given-names></name><name><surname>Look</surname><given-names>PC</given-names></name><name><surname>Chong</surname><given-names>LY</given-names></name><name><surname>But</surname><given-names>PPH</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name></person-group><article-title>A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis</article-title><source>Int J Dermatol</source><year>1999</year><volume>38</volume><fpage>387</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10369553</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latchman</surname><given-names>Y</given-names></name><name><surname>Whittle</surname><given-names>B</given-names></name><name><surname>Rustin</surname><given-names>M</given-names></name><name><surname>Atherton</surname><given-names>DJ</given-names></name><name><surname>Brostoff</surname><given-names>J</given-names></name></person-group><article-title>The efficacy of traditional Chinese herbal therapy in atopic eczema</article-title><source>Int Arch Allergy Immunol</source><year>1994</year><volume>104</volume><fpage>222</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8032233</pub-id></element-citation></ref></ref-list></back></article>